Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject understands the study procedures and agrees to participate in the study by giving written informed consent.~* Subject is 18 years of age or older.~* Subject agrees to not participate in another study of an investigational agent during the study.~* Subject must be receiving hemodialysis 3 times weekly for at least 3 months~* Other Inclusion Criteria may apply~Exclusion Criteria:~* Currently receiving treatment in another investigational device or drug study, or ended treatment on another investigational device or drug study(s) within 8 weeks prior to screening.~* Other investigational procedures while participating in this study are excluded.~* Anticipated or scheduled parathyroidectomy during the study period.~* Subject has received a parathyroidectomy within 3 months prior to dosing.~* Anticipated or scheduled kidney transplant during the study period.~* Subject has known sensitivity to any of the products or components to be administered during dosing.~* Subject has participated in a prior clinical trial of AMG 416~* Subject has an unstable medical condition based on medical history, physical examination, and routine laboratory tests, or is otherwise unstable in the judgment of the Investigator.~* Subject has a history of any illness that, in the opinion of the Investigator, might confound the results of the study or pose additional risk to the subject.~* Other Exclusion Criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo administered by intravenous bolus injection at the end of each hemodialysis session, three times per week (TIW) for 26 weeks.
- Etelcalcetide (Type: EXPERIMENTAL): Participants received etelcalcetide administered by intravenous bolus injection at the end of each hemodialysis session TIW for 26 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).